跳至主要内容
临床试验/NCT01557283
NCT01557283已完成不适用

An Observational Study of the Real Life Management of the Psoriasis Patients Treated With Enbrel According to the New Reimbursement Criteria - Beflex Study

Pfizer1 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2011年9月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Pfizer
入组人数
140
试验地点
1
主要终点
Number of Weeks of Etanercept Treatment

研究概览

简要总结

With the new reimbursement criteria, we want:

To describe the average treatment duration of patients with Enbrel expressed as a number of weeks/year.

To describe the number of patients who receive continuous treatment To describe the number of patients who receive intermittent treatment To describe the number of weeks off treatment

详细描述

100 patients will be followed for at least 1 year

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient restarts or is starting treatment with Enbrel for his/her psoriasis in alignment with reimbursement criteria
  • Patients ≥18 year
  • Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

排除标准

  • 未提供

结局指标

主要结局

Number of Weeks of Etanercept Treatment

时间窗: Baseline up to end of study (90 weeks)

Average duration of time in weeks for treatment with etanercept was reported.

次要结局

  • Number of Weeks of Off-Treatment(Baseline up to end of study (90 weeks))
  • Psoriasis Area and Severity Index (PASI) Score(Start and end of cycle 1, 2, 3)
  • Percentage of Body Surface Area (BSA) Affected by Psoriasis(Start and end of cycle 1, 2, 3)
  • Number of Participants With Reasons for Treatmant Discontinuation(Baseline up to end of study (90 weeks))

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验